Journal Homepage: www.ijarpr.com ISSN: 3049-0103 (Online)

International Journal of Advance Research Publication and Reviews

Vol 03, Issue 10, pp 372-379, October, 2026

# Pathophysiology and Pharmacotherapy of Cholelithiasis: A Comprehensive Review.

***Sanusha T.V [1], Dr. Abdul Vahab A. [2], Dr. Jyoti Harindran [3]***

*M. Pharm student [1], Professor [2], Principal, Department of Pharmaceutical Sciences [3]*

*Department of pharmaceutical sciences, Department of pharmaceutical science road, cheruvandoor, ettumanoor, Kottayam, pin 686631*

**ABSTRACT**

Cholelithiasis represents a widespread metabolic and hepatobiliary disorder affecting up to twenty percent of adults worldwide, contributing to substantial morbidity, direct healthcare expenditures, and diminished quality of life. The clinical cornerstone of definitive intervention remains laparoscopic cholecystectomy; however, surgical excision does not resolve the root metabolic aberrations governing lithogenesis and disrupts endogenous enterohepatic bile acid circulation, carrying secondary risks of postcholecystectomy diarrhea, metabolic syndrome, and altered gut microbiome dynamics. Understanding the mechanistic foundations of cholesterol and pigment gallstone formation has unveiled promising pharmacological targets. Supersaturation of bile with cholesterol arises from coordinated dysregulation across hepatic lipid transporters, defective nuclear receptor signaling, hypersecretion of gallbladder mucin, impaired neurohormonal contractility, and accelerated hydrophobic crystallization. While ursodeoxycholic acid (UDCA) serves as the primary non-surgical therapeutic agent, its prolonged treatment duration, incomplete dissolution efficacy against calcified or mixed stones, and post-cessation recurrence rates highlight the necessity for optimized medical alternatives. Emerging approaches focus on dual therapies combining bile desaturating agents with intestinal cholesterol uptake blockers, selective nuclear receptor agonists, and antioxidant-rich plant bioactives capable of attenuating inflammatory and oxidative insults within the biliary epithelium. Furthermore, translating these interventions through targeted genetic risk stratification and tailored combination regimens offers a viable route toward organ-preserving pharmacotherapy. This comprehensive review delineates the pathophysiology, molecular transport networks, conventional medications, novel drug candidates, and preclinical natural bioactives in cholelithiasis, providing an integrated roadmap for non-surgical hepatobiliary care.

**Keywords:** Cholelithiasis; Pathophysiology; Pharmacotherapy; Ursodeoxycholic acid; ABCG5/ABCG8; Phytotherapy; Bile acid metabolism.

## 1. Introduction

Cholelithiasis, or gallstone disease, remains one of the most prevalent and costly gastrointestinal pathologies globally [1]. Epidemiological surveys indicate that gallstones develop in 10% to 20% of European and American adults, with rising prevalence across transitioning economies attributed to shifting dietary patterns, urban sedentary lifestyles, and escalating rates of obesity and metabolic syndrome [1, 2] .While approximately 80% of affected individuals remain asymptomatic throughout life, symptomatic progression introduces complications such as biliary colic, acute cholecystitis, choledocholithiasis, cholangitis, and gallstone pancreatitis [3] .

Historically, cholecystectomy has stood as the definitive standard of care. While minimally invasive laparoscopic techniques have mitigated perioperative recovery times, surgical removal is inherently ablative. Ablating the gallbladder permanently alters the reservoir kinetics of bile acids, exposing the duodenal mucosa and proximal colon to continuous, unbuffered bile acid flux [4, 5]. This altered enterohepatic circulation has been associated with metabolic sequelae, including increased hepatic triglyceride synthesis, dyslipidemia, metabolic dysfunction-associated steatotic liver disease (MASLD), and colorectal neoplasia risks [5, 6]. Consequently, non-surgical pharmacotherapy aimed at organ preservation and underlying metabolic correction represents an active area of pharmacological investigation [7].

## 2. Etiology and Classification of Gallstones

Gallstones are categorized into three primary phenotypes based on chemical composition:

1. **Cholesterol Gallstones:** Account for greater than 80% to 90% of cases in industrialized and Westernized societies [1, 7]. They consist

predominantly of crystalline cholesterol monohydrate (>70% by weight) embedded in a matrix of mucin glycoproteins, calcium salts, and bilirubin [8].

2. **Black Pigment Stones:** Composed primarily of insoluble calcium bilirubinate and copper salts. These stones typically arise in the setting of chronic intravascular hemolysis (e.g., sickle cell anemia, thalassemia), liver cirrhosis, or prolonged total parenteral nutrition [8, 9].

3. **Brown Pigment Stones:** Characterized by soft, earthy concretions containing calcium bilirubinate, calcium palmitate, and bacterial degradation products. They frequently form secondary to anaerobic bacterial infection and bile stasis directly within the intrahepatic and extrahepatic biliary ducts [9, 10] .

| Gallstone Type | Primary Chemical Constituents | Major Etiological Drivers | Primary Anatomical Site | Clinical Significance |
|---|---|---|---|---|
| Cholesterol Stones | Cholesterol monohydrate (>70%), mucin, calcium carbonate | Hepatic cholesterol hypersecretion, hypomotility, metabolic syndrome [1, 8] | Gallbladder | Responsive to medical dissolution therapies |
| Black Pigment Stones | Insoluble calcium bilirubinate, polymer matrices, copper | Chronic hemolysis, liver cirrhosis, prolonged parenteral nutrition [8, 9] | Gallbladder | Radiopaque; unyielding to bile acid dissolution |
| Brown Pigment Stones | Calcium bilirubinate, calcium soaps, bacterial remnants | Biliary stasis, bacterial cholangitis (*E. coli*, *Klebsiella*) [9, 10] | Common and intrahepatic ducts | Recurrent post-surgical risk; requires antimicrobial and decompression care |

## 3. Pathophysiology and Molecular Transporter Networks

The formation of cholesterol gallstones requires a coordinated cascade of pathological events: hepatic hypersecretion leading to supersaturation of bile, delayed gallbladder emptying, accelerated crystal nucleation, and mucin gel accumulation [11]. The initial trigger involves the uncoupling of hepatic cholesterol export from bile acid and phospholipid secretion, driven primarily by the upregulation of canalicular sterol transporters alongside the suppression of bile acid synthetic enzymes like CYP7A1[11, 12]. When the resulting cholesterol concentration surpasses the carrying capacity of mixed micelles, the Cholesterol Saturation Index exceeds 1.0, generating a thermodynamically unstable environment prone to phase separation [12]. Concurrently, persistent biliary stasis, blunted neurohormonal contractility, and mucosal inflammation stimulate the transcriptional hypersecretion of gel-forming mucins (*MUC5AC*, *MUC5B*) [19, 21]. This dense polymeric network serves as an architectural scaffold, trapping hydrophobic microcrystals and accelerating their agglomeration into macroscopic biliary calculi [20, 21].

### *3.1 Hepatic Cholesterol Hypersecretion and Transporter Cascades*

Under normal physiological conditions, hydrophobic cholesterol is solubilized within bile inside mixed micelles composed of bile salts and phospholipids (predominantly phosphatidylcholine) [11, 12]. When cholesterol mass exceeds the solubilizing capacity of micelles and vesicles, the Cholesterol Saturation Index (CSI) exceeds 1.0, rendering bile lithogenic [12].

This saturation is driven by canalicular membrane transporters [13]:

- **ABCG5 and ABCG8:** The heterodimeric ATP-binding cassette transporter complex ABCG5/ABCG8 constitutes the rate-limiting gate for biliary cholesterol secretion [13, 14]. Overexpression of these transporters or gain-of-function polymorphisms (such as *ABCG8* D19H) directly elevates biliary cholesterol output [14].

- **ABCB4 (MDR3):** Mediates the canalicular translocation of phosphatidylcholine, the vital phospholipid required to generate mixed micelles and buffer cholesterol toxicity [15]. Defective ABCB4 function precipitates low phospholipid-associated cholelithiasis (LPAC syndrome) [15].

- **ABCB11 (BSEP):** The Bile Salt Export Pump actively drives the canalicular secretion of monovalent bile acid salts, supplying the osmotic driving force for bile flow. Suppression of BSEP dampens the solvent power of bile, accelerating crystallization [16].

### *3.2 Nuclear Receptor Signaling (FXR, LXR, TGR5)*

Canalicular transporter expression and bile acid synthesis are tightly orchestrated by nuclear and membrane-bound receptors [17]:

- **Farnesoid X Receptor (FXR; NR1H4):** Activated primarily by chenodeoxycholic acid (CDCA) and cholic acid (CA). Hepatic FXR activation upregulates *ABCB11* (BSEP) and *ABCB4* (MDR3) while repressing *CYP7A1* (the rate-limiting enzyme in bile acid synthesis) via the small heterodimer partner (SHP) and ileal FGF15/19 axes [17, 18].

- **Liver X Receptor (LXR; NR1H3):** Acts as an intracellular oxysterol sensor. Activation of hepatic LXR upregulates *ABCG5/G8*, driving cholesterol hypersecretion into the biliary tree [18].

- **Takeda G-Protein Receptor 5 (TGR5):** A G-protein-coupled receptor responsive to secondary bile acids (e.g., lithocholic acid). TGR5 signaling in gallbladder smooth muscle promotes relaxation and filling, while in epithelial cholangiocytes it stimulates fluid secretion, directly influencing organ motility and bile concentration [19].

### *3.3 Gallbladder Hypomotility and Mucin Hypersecretion*

Biliary stasis provides the necessary incubation period for microscopic microcrystals to aggregate into macroscopic stones [19, 20]. Gallbladder hypomotility stems from blunted cholecystokinin (CCK) receptor sensitivity, increased caveolin-1-mediated cholesterol entrapment in smooth muscle sarcolemma, and local neurohormonal decoupling [20]. Concurrently, chronic biliary irritation triggers mucosal hypersecretion of high-molecular-weight gel-forming mucins (*MUC5AC*, *MUC5B*), creating a viscous mucin gel matrix that accelerates solid cholesterol crystal nucleation [21].

## 4. Conventional Pharmacotherapy and Current Limitations

For decades, non-surgical management has relied on oral bile acid dissolution therapy [22].

### *4.1 Ursodeoxycholic Acid (UDCA)*

UDCA, a hydrophilic secondary bile acid naturally occurring in small concentrations in humans, remains the pharmacological reference standard [22, 23].

- **Mechanisms of Action:** UDCA displaces cytotoxic hydrophobic bile acids (deoxycholic and lithocholic acids) from the circulating pool, reducing hepatic cholesterol synthesis and fractional absorption, and promoting liquid-crystalline phase dispersal of cholesterol from the stone surface [23].

- **Clinical Efficacy and Indications:** Effective primarily in radiolucent (non-calcified), small (<5–10 mm), high-cholesterol content stones within a patent, functioning gallbladder [22, 24].

- **Limitations:** Complete dissolution often requires 6 to 24 months of consistent daily therapy (10–15 mg/kg/day). Recurrence rates reach 30% to 50% within five years following treatment cessation, primarily because systemic metabolic drivers and gallbladder stasis persist unaddressed [24, 25].

### *4.2 Chenodeoxycholic Acid (CDCA)*

CDCA was the initial bile acid deployed for gallstone dissolution. While effective in suppressing HMG-CoA reductase and desaturating bile, its extensive therapeutic utility is constrained by dose-dependent secretory diarrhea and hepatotoxicity manifesting as elevated serum transaminases [25, 26].

## 5. Emerging Molecular Targets and Synthetic Therapeutics

Given the limitations of monotherapy with UDCA, translational research has targeted complementary mechanisms across the enterobiliary axis [27]. In particular, inhibiting intestinal cholesterol absorption creates a negative balance that reshapes hepatic and biliary sterol trafficking [28]. Free cholesterol originating from dietary intake and recirculated bile is internalized at the brush-border membrane of enterocytes via the Niemann-Pick C1-Like 1 (NPC1L1) transporter. By selectively blocking this entry mechanism, pharmacotherapy depletes the regulatory intrahepatic cholesterol pool without repressing bile acid production [28, 29]. This reduction directly attenuates ABCG5/ABCG8-mediated sterol hypersecretion at the canalicular membrane, reducing the biliary cholesterol saturation index and establishing a thermodynamic environment that favors dissolution over crystallization [29].

### *5.1 Ezetimibe and Intestinal Cholesterol Absorption Inhibitors*

Ezetimibe selectively inhibits Niemann-Pick C1-Like 1 (NPC1L1), the primary enterocyte transporter facilitating free cholesterol uptake in the brush border membrane of the jejunum [28]. By shutting down intestinal absorption, ezetimibe depletes hepatic cholesterol stores without downregulating bile acid production [28, 29]. In preclinical models and clinical trials, co-administration of ezetimibe with low-dose UDCA accelerated stone dissolution and prevented lithogenic-diet-induced gallstone formation, demonstrating clear pharmacodynamic synergy [29].

### *5.2 Synthetic FXR and TGR5 Modulators*

Synthetic FXR agonists (e.g., Obeticholic acid, GW4064) hold therapeutic utility by orchestrating transporter levels: upregulating phospholipid secretion (*ABCB4*) and bile acid output (*ABCB11*), while restoring bile acid synthesis homeostasis [30]. Concurrently, dual FXR/TGR5 agonists counteract gallbladder hypomotility, clear biliary sludge, and suppress proinflammatory cytokine cascades in cholangiocytes [30, 31].

### *5.3 Statins (HMG-CoA Reductase Inhibitors)*

Statins decrease endogenous de novo cholesterol synthesis by competitively blocking HMG-CoA reductase. While epidemiological cohorts show reduced cholelithiasis risk among long-term statin users, monotherapy exhibits variable efficacy in dissolving mature stones, securing their role primarily as prophylactic or adjuvant options [32, 33].

| **Therapeutic Class** | **Exemplar Agents** | **Primary Mechanism of Action** | **Stage of Development** | **Key Benefits / Constraints** |
|---|---|---|---|---|
| Hydrophilic Bile Acids | Ursodeoxycholic acid (UDCA) | Dispersion of liquid-crystalline mesophase; competitive suppression of hydrophobic bile acids [22, 23] | Clinical standard (FDA-approved) | Safe, non-invasive; limited to small, radiolucent stones; high recurrence [24] |
| NPC1L1 Inhibitors | Ezetimibe | Blocks intestinal free cholesterol uptake via enterocyte NPC1L1 [28] | Phase II/III clinical evaluation | Synergistic with UDCA; drastically reduces CSI; requires combination use [29] |
| Synthetic FXR Agonists | Obeticholic acid (OCA) | Upregulates BSEP and MDR3; suppresses CYP7A1; dampens mucosal inflammation [17, 30] | Preclinical & exploratory clinical | Restores bile salt/phospholipid ratio; potential pruritus and lipid shift [30] |
| HMG-CoA Reductase Inhibitors | Atorvastatin, Rosuvastatin | Inhibits de novo hepatic cholesterol synthesis [32] | Clinical observational & adjuvant | Reduces lithogenic risk profile; inadequate as single-agent dissolution [33] |

## 6. Natural Products and Phytotherapeutics in Cholelithiasis

Bioactive plant secondary metabolites, notably polyphenols, flavonolignans, and flavonoids, exhibit pleiotropic pharmacological activities that counteract several lithogenic mechanisms simultaneously [34]. Through their potent antioxidant activity, these compounds scavenge reactive oxygen species and inhibit lipid peroxidation in the gallbladder wall and canalicular membranes [34, 39]. Concurrently, specific phytoconstituents induce *CYP7A1* expression, stimulating the metabolic conversion of cholesterol into hydrophilic bile acids and expanding the bile salt pool [39, 40]. Furthermore, by suppressing nuclear factor kappa B (NF-κB) activation, these natural bioactives downregulate the hypersecretion of gel-forming mucins (*MUC5AC* and *MUC5B*), thereby destabilizing the polymeric matrix necessary for cholesterol nucleation and facilitating biliary clearance [35, 36].

### *6.1 Curcumin (Curcuma longa)*

Curcumin exhibits profound cholekinetic, antioxidant, and anti-inflammatory properties. Mechanistically, it stimulates gallbladder emptying by upregulating endogenous CCK release, suppresses mucosal *MUC5AC* overexpression via NF-κB inhibition, and reduces lipid peroxidation in the gallbladder wall [35, 36].

### *6.2 Silymarin (Silybum marianum)*

The flavonolignan complex silymarin, predominantly comprising silybin, stimulates biliary phospholipid secretion, enhances biliary bile acid output, and preserves hepatocyte canalicular membrane fluidity against toxic lithogenic diets [37, 38].

### *6.3 Flavonoids and Bioactive Polyphenols*

Dietary polyphenols, including quercetin, resveratrol, and catechins, upregulate *CYP7A1* transcription, promoting the conversion of cholesterol into hydrophilic bile acids [39, 40]. Concurrently, their potent free-radical scavenging capacity protects membrane-bound enzymes and transport proteins from reactive oxygen species generated during persistent biliary stasis [40].

| Natural Source / Plant | Key Bioactive Constituents | Experimental Model | Proposed Pharmacological Mechanism | Reference |
|---|---|---|---|---|
| Curcuma longa (Turmeric) | Curcumin, Demethoxycurcumin | Mice on lithogenic diet; human trials | CCK stimulation; NF-κB inhibition; downregulates MUC5AC and MUC5B mucin gels | [35, 36] |
| Silybum marianum (Milk Thistle) | Silymarin, Silybin | High-cholesterol rodent models | Enhances biliary phosphatidylcholine secretion; restores membrane integrity | [37, 38] |
| Alternanthera sessilis / Leaf Extracts | Flavonoids, Polyphenols, Saponins | Lithogenic diet-fed rodent models | Attenuates hepatic oxidative stress; improves biliary cholesterol saturation index | [39, 41] |
| Camellia sinensis (Green Tea) | Epigallocatechin gallate (EGCG) | C57BL/6 lithogenic models | Downregulates intestinal NPC1L1; suppresses canalicular ABCG5/G8 overexpression | [40, 42] |

## 7. Translational Perspectives: Towards Personalized Non-Surgical Therapy

A durable and clinically viable non-surgical treatment paradigm requires moving beyond empirical monotherapy toward precision-guided therapeutic regimens.

### *7.1 Targeted Risk Stratification*

Targeted risk stratification serves as a pivotal entry point for proactive, non-surgical intervention in cholelithiasis. Identifying high-risk patient cohorts prior to irreversible macroscopic stone aggregation relies heavily on precision molecular and clinical screening. High-throughput genotyping allows for the detection of critical lithogenic polymorphisms, particularly the *ABCG8* D19H gain-of-function variant that drives continuous hepatic cholesterol hypersecretion into bile. In parallel, systematic surveillance of populations experiencing rapid metabolic shifts—most notably post-bariatric surgery cohorts and patients on extreme hypocaloric diets—captures early transient states of biliary supersaturation. Stratifying patients based on these distinct genetic and metabolic vulnerabilities ensures that pharmacological countermeasures are deployed selectively and during the earliest, most reversible phases of lithogenesis.

### *7.2 Combination Regimens*

In tandem with precise risk identification, multi-agent combination regimens provide the synergistic biochemical pressure required to overcome the pharmacodynamic limitations of monotherapy. While conventional treatment relies primarily on ursodeoxycholic acid (UDCA) to desaturate bile and disrupt liquid-crystalline phases, pairing it with ezetimibe provides complementary action by blocking Niemann-Pick C1-Like 1 (NPC1L1)-mediated intestinal cholesterol uptake, effectively reducing the hepatic cholesterol substrate pool. Furthermore, the integration of targeted plant bioactives introduces potent antioxidant and anti-inflammatory coverage, attenuating gallbladder hypomotility, mucin hypersecretion, and oxidative degradation of bile acids. By addressing both luminal saturation and mucosal dysmotility, these personalized dual and adjuvant therapies significantly accelerate gallstone dissolution kinetics, mitigate post-dissolution recurrence, and avert invasive cholecystectomy while preserving endogenous enterohepatic physiology.

## 8. Discussion and Future Scope

Cholelithiasis represents a multifaceted systemic metabolic disease that manifests locally as gallbladder concretions [1, 7]. The long-standing reliance on cholecystectomy as the first and often only treatment option reflects the historical lack of rapid, non-invasive pharmacological interventions [4]. However, emerging evidence detailing post-surgical metabolic dysregulation highlights the importance of re-evaluating organ-preserving therapeutic strategies [5, 6].

The primary barrier in medical dissolution therapy has been the prolonged duration required for single-agent UDCA to achieve complete clearance,

alongside significant post-dissolution recurrence rates [23, 24]. The translational roadmap outlined in this review addresses this challenge by targeting multiple nodes across the enterobiliary axis. By pairing UDCA (which promotes liquid-crystalline cholesterol solubilization) with ezetimibe (which halts intestinal uptake), the hepatic and biliary cholesterol burden is lowered more rapidly and effectively than with either drug alone [28, 29]. Adding phytotherapeutic agents further expands this therapeutic coverage by reducing local inflammation, mitigating oxidative membrane damage, and downregulating pro-nucleating mucins [35, 41].

Moving this framework forward requires prioritizing several areas in translational pharmacology:

1. **Clinical Validation of Combination Regimens:** Well-powered, randomized clinical trials are needed to assess the safety, kinetics, and recurrence outcomes of dual UDCA-ezetimibe therapy alongside standardized bioactive plant formulations [29, 36].

2. **Biomarker Development:** Validating circulating or imaging biomarkers that track early biliary cholesterol supersaturation and crystallization will enable timely intervention before macroscopic stones solidify [14, 43].

3. **Advanced Drug Delivery Platforms:** Developing hepatotropic nanoparticles and bile-targeted nanocarriers could enhance the bioavailability and site-specific accumulation of natural polyphenols and synthetic nuclear receptor agonists, minimizing systemic adverse effects [30, 44].

## 9. Conclusion

Cholelithiasis is a complex disease driven by hepatic transporter dysregulation, nuclear receptor decoupling, biliary supersaturation, gallbladder hypomotility, and mucin-assisted crystal nucleation. While laparoscopic surgery provides rapid anatomical resolution, it leaves underlying metabolic vulnerabilities unaddressed and disrupts physiological enterohepatic circulation. Advances in understanding the ABCG5/G8, FXR, and NPC1L1 signaling pathways offer clear targets for non-surgical alternatives. By uniting targeted molecular risk stratification with multi-target combination therapies—combining hydrophilic bile acids, intestinal uptake blockers, and antioxidant-rich plant bioactives—pharmacotherapy can provide effective, non-invasive, and organ-preserving management for cholelithiasis.

**REFERENCES**


1. Lammert F, Gurusamy K, Ko CW, Miquel JF, Méndez-Sánchez N, Portincasa P, et al. Gallstones. Nat Rev Dis Primers. 2016;2:16024.

2. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part III: liver, biliary, and pancreatic diseases. Gastroenterology. 2009;136(4):1134-44.

3. Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368(9531):230-9.

4. Soper NJ, Stockmann PT, Dunnegan DL, Ashley SW. Laparoscopic cholecystectomy: the new 'gold standard'? Arch Surg. 1992;127(8):917-21.

5. Roda E, Aldini R, Bazzoli F, Festi D, Mazzella G, Roda A, et al. Enterohepatic circulation of bile acids after cholecystectomy. Gut. 1978;19(7):640-9.

6. Housset C, Chrétien Y, Debray D, Chignard N. Functions of the gallbladder. Compr Physiol. 2016;6(3):1549-77.

7. Di Ciaula A, Wang DQ, Portincasa P. An update on the pathogenesis of cholesterol gallstone disease. Curr Opin Gastroenterol. 2018;34(2):71-80.

8. Trotman BW, Soloway RD. Pigment versus cholesterol cholelithiasis: clinical and epidemiological aspects. Am J Dig Dis. 1975;20(8):735-40.

9. Stewart L, Ponce R, Obremskey WT, Way LW. Pigment gallstones: chemical analysis of five types. J Gastrointest Surg. 2002;6(5):657-65.

10. Maki T. Pathogenesis of calcium bilirubinate gallstone: role of E. coli, beta-glucuronidase and coagulation by inorganic ions, polyelectrolytes and mucin. Ann Surg. 1966;164(1):90-100.

11. Admirand WH, Small DM. The physicochemical basis of cholesterol gallstone formation in man. J Clin Invest. 1968;47(5):1043-52.

12. Carey MC, Small DM. The physical chemistry of cholesterol solubility in bile: relationship to gallstone formation and dissolution in man. J Clin Invest. 1978;61(4):998-1026.

13. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290(5497):1771-5.

14. Buch S, Schafmayer C, Völzke H, Becker C, Franke A, von Eller-Eberstein H, et al. A genome-wide association scan identifies the hepatic sterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet. 2007;39(8):995-9.

15. Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Lancet. 2001;358(9276):100-4.

16. Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet. 1998;20(3):233-8.

17. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, et al. Identification of a nuclear receptor for bile acids. Science. 1999;284(5418):1362-5.

18. Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. 2000;16:459-81.

19. Kawamata Y, Fujii R, Hosoya M, Harada M, Yoshida H, Miwa M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem. 2003;278(11):9435-40.

20. Xiao ZL, Chen Q, Biancani P, Behar J. Abnormalities of gallbladder muscle associated with human cholesterol gallstones. Am J Physiol Gastrointest Liver Physiol. 2000;278(4):G543-51.

21. Lee SP, LaMont JT, Carey MC. Role of gallbladder mucus hypersecretion in the evolution of cholesterol gallstones. J Clin Invest. 1981;67(6):1712-23.

22. Tint GS, Salen G, Colalillo A, Sachs D, Narula N, Batta AK, et al. Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones. Ann Intern Med. 1982;97(3):351-6.

23. Roma MG, Toledo FD, Boaglio AC, Sanchez Pozzi EJ, Basiglio CL, Crocenzi FA. Ursodeoxycholic acid in cholestasis: all for one and one for all. Life Sci. 2011;89(15-16):515-28.

24. Petroni ML, Jazrawi RP, Goggin PM, Lanzini A, Zuin M, Cartei G, et al. Characteristics of gallbladder stones that predict response to dissolution therapy with bile acids. Gut. 1992;33(5):699-704.

25. Danzinger RG, Hofmann AF, Schoenfield LJ, Thistle JL. Dissolution of cholesterol gallstones by chenodeoxycholic acid. N Engl J Med. 1972;286(1):1-8.

26. Schoenfield LJ, Lachin JM. Chenodiol (chenodeoxycholic acid) for dissolution of gallstones: the National Cooperative Gallstone Study. Ann Intern Med. 1981;95(3):257-82.

27. Portincasa P, Ciaula AD, Bonfrate L, Wang DQ. Therapy of gallstone disease: What it was, what it is, what it will be. World J Gastrointest Pharmacol Ther. 2012;3(2):7-20.

28. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci U S A. 2005;102(23):8132-7.

29. Wang DQ, Cohen DE, Carey MC. Ezetimibe prevents gallstone formation by inhibiting intestinal cholesterol absorption in mice. Gastroenterology. 2003;124(4):A-537.

30. Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45(17):3569-72.

31. Fiorucci S, Cipriani S, Mencarelli A, Renga B, Distrutti E. Counter-regulatory role of bile acid activated receptors in immunity and inflammation. Curr Mol Med. 2010;10(6):579-95.

32. Bodmer M, Brauchli YB, Krähenbühl S, Jick SS, Meier CR. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA. 2009;302(18):2001-7.

33. Erichsen R, Frøslev T, Lash TL, Pedersen L, Sørensen HT. Long-term statin use and the risk of gallstone disease: a population-based case-control study. Am J Epidemiol. 2011;173(2):162-70.

34. Bone K, Mills S. Principles and Practice of Phytotherapy: Modern Herbal Medicine. 2nd ed. Edinburgh: Churchill Livingstone; 2013.

35. Rasyid A, Lelo A. The effect of curcumin and placebo on human gall-bladder motility: double-blind study. Aliment Pharmacol Ther. 1999;13(2):245-9.

36. Li Y, Li M, Wu S, Tian Y. Curcumin attenuates diet-induced cholesterol gallstones by inhibiting hepatic NPC1L1 and ABCG5/G8 expression and reducing gallbladder mucin secretion. Phytomedicine. 2015;22(1):92-100.

37. Crocenzi FA, Roma MG. Silymarin as a new approach to treat cholestasis: how far are we? Clin Sci (Lond). 2006;110(3):285-98.

38. Nassuato G, Iemmolo RM, Strazzabosco M, Lirussi F, Deana R, Francesconi MA, et al. Effect of silibinin on biliary lipid secretion in the rat. Biochem Pharmacol. 1991;42(6):1259-67.

39. Srinivasan K. Plant foods in the management of hypercholesterolemia and cholelithiasis: experimental evidence and mechanisms. Crit Rev Food Sci Nutr. 2014;54(8):1038-54.

40. Babu PVA, Liu D. Green tea catechins and cardiovascular health: an update. Curr Med Chem. 2008;15(18):1840-50.

41. Subhashini K, Ravichandran V. Phytochemical profile and antioxidant capacity of *Alternanthera sessilis*: therapeutic potential against metabolic pathologies. J Ethnopharmacol. 2018;214:122-31.

42. Geetha K, Jayanthi S. Green tea polyphenols attenuate biliary lithogenesis in high-fat high-cholesterol murine models. Hepatol Res. 2016;46(7):688-97.

43. Venneman NG, Renooij W, Rehfeld JF, vanBerge-Henegouwen GP, Go PM, Broeders IA, et al. Small gallstones, preserved gallbladder motility, and fast crystallization are associated with pancreatitis. Hepatology. 2005;41(4):738-45.

44. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813-27.